Skip to main content
Premium Trial:

Request an Annual Quote

Wall Street Rewards Caliper Life Sciences on 22-Percent Q3 Revenue Growth

This article has been updated to include stock price.

NEW YORK, Nov. 5 (GenomeWeb News) - Shares in Caliper Life Sciences were up 4 percent to $7.02 in mid-afternoon trade after the company reported a 22-percent jump in third-quarter revenue and narrowed net losses.

 

Caliper said that increased interest from pharmaceutical companies in its microfluidic screening platform helped drive revenue in the period to $20.2 million from $16.5 million year over year.

 

The company said that during the last three months, Merck, Johnson & Johnson, and Taisho Pharmaceutical of Japanhad each purchased a LabChip 3,000 microfluidic screening system for the first time. In addition, Aventis and Pfizer recently bought additional systems, according to the company.

 

Caliper spent $5.3 million on R&D during the quarter, down from $8.8 million a year ago.

 

The company's net loss was cut in half, to $5.1 million, or $.17 per share, compared to $10.1 million, or $.37 per share, during the third quarter of 2003.

 

As of Sept. 30, Caliper had $6.1 million in cash and cash equivalents and $43.1 million in short-term marketable securities.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.